Showing results (2641-2650 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignanciesDavid C Smith, Thea Kalebic, Jeffrey R Infante, et al.
Investigational New Drugs|August 5, 2020
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in KoreaMin Jin Lee, Sung Won Chang, Ji Hoon Kim, et al.
Investigational New Drugs|April 8, 2021
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatmentXiaoping Song, Wei Tang, Hui Peng, et al.
Investigational New Drugs|September 19, 2012
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomographySeung Jin Lee, Eun Jung Kim, Haeng Jung Lee, et al.
Investigational New Drugs|September 22, 2012
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunctionJ P Delord, A Ravaud, J Bennouna, et al.
Investigational New Drugs|August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumorsAmir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Investigational New Drugs|September 12, 2012
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicinTetsuya Tanimoto, Masaharu Tsubokura, Jinichi Mori, et al.
Investigational New Drugs|September 1, 2012
Development of artemisinin compounds for cancer treatmentHenry C Lai, Narendra P Singh, Tomikazu Sasaki
Investigational New Drugs|September 8, 2012
Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiationElad Milrot, Anna Jackman, Eliezer Flescher, et al.
Investigational New Drugs|May 4, 2023
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patientsXueyun Tan, Sufei Wang, Hui Xia, et al.
Pageof 372